13. Multiple sclerosis/Neuromyelitis optica Clinical trials / Disease details
Clinical trials : 3,342 / Drugs : 2,355 - (DrugBank : 406) / Drug target genes : 269 - Drug target pathways : 241
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT05092191 (ClinicalTrials.gov) | December 15, 2021 | 1/9/2021 | Cannabis as a Complementary Treatment in Multiple Sclerosis | Efficacy of Cannabinoids to the Current Standard Treatments on Symptom Relief in Persons With Multiple Sclerosis: Randomized Controlled Trial | Multiple Sclerosis | Drug: Cannabis oil vs placebo | Centre hospitalier de l'Université de Montréal (CHUM) | Canadian Institutes of Health Research (CIHR);Multiple Sclerosis Society of Canada | Not yet recruiting | 21 Years | N/A | All | 250 | Phase 3 | NULL |
| 2 | EUCTR2018-002315-98-DK (EUCTR) | 06/12/2018 | 09/07/2018 | The effect of cannabis products on nerve pain and muscle stiffness in patients with multiple sclerosis and in patients with spinal cord injury. | The effect of medical cannabis on neuropathic pain and spasticity in patients with Multiple Sclerosis and in patients with spinal cord injury. A multicenter national placebo-controlled trial - The effect of medical cannabis on neuropathic pain and spasticity in patients with MS and SCI | Central neuropathic pain and spasticity MedDRA version: 20.0;Level: PT;Classification code 10028335;Term: Muscle spasticity;System Organ Class: 10029205 - Nervous system disorders MedDRA version: 20.0;Level: LLT;Classification code 10077975;Term: Central neuropathic pain;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Name: Cannabidiol capsule 5 mg Product Code: N/A INN or Proposed INN: Cannabidiol Other descriptive name: CBD Product Name: Dronabinol capsule 2,5 mg Product Code: N/A INN or Proposed INN: DRONABINOL Other descriptive name: THC Product Name: Cannabidiol / Dronabinol capsule 5 mg+2,5 mg Product Code: N/A INN or Proposed INN: DRONABINOL Other descriptive name: THC INN or Proposed INN: Cannabidiol Other descriptive name: CBD | Aarhus Universitetshospital | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 448 | Phase 2 | Denmark | ||
| 3 | NCT03944447 (ClinicalTrials.gov) | December 1, 2018 | 3/5/2019 | Outcomes Mandate National Integration With Cannabis as Medicine for Prevention and Treatment of COVID-19 | Outcomes Mandate National Integration With Cannabis as Medicine for Prevention and Treatment of COVID-19 | Chronic Pain;Chronic Pain Syndrome;Chronic Pain Due to Injury;Chronic Pain Due to Trauma;Fibromyalgia;Seizures;Hepatitis C;Cancer;Crohn Disease;HIV/AIDS;Multiple Sclerosis;Traumatic Brain Injury;Sickle Cell Disease;Post Traumatic Stress Disorder;Tourette Syndrome;Ulcerative Colitis;Glaucoma;Epilepsy;Inflammatory Bowel Diseases;Parkinson Disease;Amyotrophic Lateral Sclerosis;Chronic Traumatic Encephalopathy;Anxiety;Depression;Insomnia;Autism;Opioid-use Disorder;Bipolar Disorder;Covid19;SARS-CoV Infection;COVID-19;Corona Virus Infection;Coronavirus | Drug: Cannabis, Medical;Device: RYAH-Medtech Inhaler | OMNI Medical Services, LLC | OMNI Medical Services Inc | Recruiting | 7 Years | N/A | All | 200000 | Phase 2 | United States |
| 4 | NCT03172741 (ClinicalTrials.gov) | January 2017 | 25/5/2017 | The Effects of Different Medical Marijuana Strains on Motor and Cognitive Function in People With Multiple Sclerosis | The Effects of Different Medical Marijuana Strains on Motor and Cognitive Function in People With Multiple Sclerosis | Multiple Sclerosis | Drug: Medical Marijuana;Drug: Placebo | Colorado State University | NULL | Withdrawn | 21 Years | 74 Years | All | 0 | Phase 2/Phase 3 | NULL |
| 5 | NCT02898974 (ClinicalTrials.gov) | September 2016 | 6/9/2016 | Medical Marijuana and Its Effects on Motor Function in People With Multiple Sclerosis | Medical Marijuana and Its Effects on Motor Function in People With Multiple Sclerosis: An Observational Case-control Study | Multiple Sclerosis | Behavioral: Medical Marijuana | Colorado State University | William R. Shaffer, M.D. | Completed | 30 Years | 60 Years | All | 22 | United States | |
| 6 | NCT01037088 (ClinicalTrials.gov) | December 2009 | 17/12/2009 | Effects of Vaporized Marijuana on Neuropathic Pain | CCRC: The Analgesic Effect of Vaporized Cannabis on Neuropathic Pain | Neuropathic Pain;Reflex Sympathetic Dystrophy;Peripheral Neuropathy;Post-herpetic Neuralgia;Spinal Cord Injury;Multiple Sclerosis | Drug: Mild dose cannabis;Drug: Low dose cannabis;Drug: Cannabis | University of California, Davis | Center for Medicinal Cannabis Research;VA Northern California Health Care System | Completed | 18 Years | 70 Years | All | 44 | Phase 1/Phase 2 | United States |
| 7 | NCT00552604 (ClinicalTrials.gov) | June 2006 | 1/11/2007 | MUltiple Sclerosis and Extract of Cannabis (MUSEC) Study | Randomised, Double-blind, Placebo-controlled Phase III Trial to Determine the Efficacy and Safety of a Standardised Oral Extract of Cannabis Sativa for the Symptomatic Relief of Muscle Stiffness and Pain in Multiple Sclerosis. | Muscle Spasticity | Drug: standardized cannabis extract;Drug: Placebo | Institut fur Klinische Forschung, Germany | Weleda AG | Terminated | 18 Years | 64 Years | Both | 279 | Phase 3 | United Kingdom |
| 8 | EUCTR2005-005263-29-GB (EUCTR) | 31/01/2006 | 09/12/2005 | Multiple Sclerosis and Extract of Cannabis (MUSEC): A randomised, double-blind, placebo-controlled phase III trial to determine the efficacy and safety of a standardised oral extract of Cannabis sativa for the symptomatic relief of muscle stiffness and pain in Multiple Sclerosis. - MUSEC study | Multiple Sclerosis and Extract of Cannabis (MUSEC): A randomised, double-blind, placebo-controlled phase III trial to determine the efficacy and safety of a standardised oral extract of Cannabis sativa for the symptomatic relief of muscle stiffness and pain in Multiple Sclerosis. - MUSEC study | Multiple Sclerosis | Product Name: Cannador | Gesellschaft fuer klinische Forschung e.V. (Society for Clinical Research) | WELEDA AG | Not Recruiting | Female: yes Male: yes | 300 | Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): no Therapeutic confirmatory - (Phase 3): yes Therapeutic use (Phase 4): no | United Kingdom | ||
| 9 | EUCTR2005-000393-47-IT (EUCTR) | 22/09/2004 | 05/03/2007 | Effect of Cannabis Based Medicine Extract Sativex on brain function as assessed by fMRI and neurophysiologic evaluation in patients with Multiple Sclerosis a double blind, randomised, placebo-controlled, crossover study. | Effect of Cannabis Based Medicine Extract Sativex on brain function as assessed by fMRI and neurophysiologic evaluation in patients with Multiple Sclerosis a double blind, randomised, placebo-controlled, crossover study. | Treatment of spasticity in patients with Multiple Sclerosis MedDRA version: 9.1;Level: LLT;Classification code 10028245;Term: Multiple sclerosis | Trade Name: Cannabis Based Medicine Extract (Sativex) | AZIENDA UNIVERSITARIA POLICLINICO UMBERTO I DI ROMA | NULL | Not Recruiting | Female: yes Male: yes | Italy | ||||
| 10 | NCT00682929 (ClinicalTrials.gov) | April 14, 2004 | 19/5/2008 | Cannabis for Spasticity in Multiple Sclerosis | Cannabis for Spasticity in Multiple Sclerosis: A Placebo-Controlled Study | Multiple Sclerosis | Drug: Inhaled Cannabis;Drug: Oral THC;Drug: Oral Placebo;Drug: Inhaled placebo | University of California, Davis | National Multiple Sclerosis Society | Terminated | 21 Years | N/A | All | 41 | Phase 1/Phase 2 | United States |
| 11 | NCT00260741 (ClinicalTrials.gov) | March 2003 | 30/11/2005 | Cannabis for Spasticity in Multiple Sclerosis | Cannabis for Spasticity in Multiple Sclerosis: A Placebo-Controlled Study | Multiple Sclerosis | Drug: Smoked Cannabis | Center for Medicinal Cannabis Research | NULL | Terminated | 21 Years | N/A | Both | 60 | Phase 1/Phase 2 | United States |
| 12 | NCT00678795 (ClinicalTrials.gov) | August 2002 | 14/5/2008 | A Parallel Group Study to Compare Sativex® With Placebo in the Treatment of Detrusor Overactivity in Patients With Multiple Sclerosis | A Double Blind, Randomised, Placebo Controlled, Parallel Group Study of Cannabis Based Medicine (CBM) Extract, in Patients Suffering Detrusor Overactivity Associated With Multiple Sclerosis. | Detrusor Overactivity;Multiple Sclerosis | Drug: Sativex®;Drug: Placebo | GW Pharmaceuticals Ltd. | NULL | Completed | 18 Years | N/A | All | 135 | Phase 3 | United Kingdom |
| 13 | NCT00711646 (ClinicalTrials.gov) | June 2002 | 8/7/2008 | A Study of Sativex® for Relief of Spasticity in Subjects With Multiple Sclerosis. | A Double Blind, Randomised, Parallel Group Study to Assess the Efficacy, Safety and Tolerability of Cannabis Based Medicine 1:1 THC:CBD Compared With Placebo for the Treatment of Spasticity in Patients With Multiple Sclerosis. | Spasticity;Multiple Sclerosis | Drug: Sativex®;Drug: Placebo | GW Pharmaceuticals Ltd. | NULL | Completed | 18 Years | N/A | All | 189 | Phase 3 | United Kingdom |
| 14 | NCT01606176 (ClinicalTrials.gov) | March 2002 | 21/5/2012 | A Study to Evaluate the Effects of Cannabis Based Medicine in Patients With Pain of Neurological Origin | A Multi Centre Randomised, Double Blind, Placebo Controlled, Parallel Group Comparison of the Effects of Cannabis Based Medicine Standardised Extracts Over 4 Weeks, in Patients With Chronic Refractory Pain Due to Multiple Sclerosis or Other Defects of Neurological Function. | Pain;Multiple Sclerosis | Drug: GW-1000-02;Drug: Placebo | GW Pharmaceuticals Ltd. | NULL | Completed | 18 Years | N/A | All | 70 | Phase 3 | United Kingdom |
| 15 | NCT01606137 (ClinicalTrials.gov) | February 2002 | 21/5/2012 | A Study of the Long-term Safety of Sativex Use | A Long-term, Open Label, Safety and Tolerability Study of Cannabis Based Medicine Extract in Patients Who Have Participated in a GW Clinical Study Using Cannabis Based Medicine. | Multiple Sclerosis;Spasticity;Pain | Drug: GW-1000-02 | GW Pharmaceuticals Ltd. | NULL | Completed | 18 Years | N/A | All | 507 | Phase 3 | United Kingdom |
| 16 | NCT00248378 (ClinicalTrials.gov) | September 2001 | 2/11/2005 | Short-Term Effects of Medicinal Cannabis Therapy on Spasticity in Multiple Sclerosis | Short-Term Effects of Medicinal Cannabis Therapy on Spasticity in Multiple Sclerosis | Multiple Sclerosis | Drug: Smoked Cannabis | Center for Medicinal Cannabis Research | NULL | Completed | 18 Years | N/A | Both | 30 | Phase 1/Phase 2 | United States |